SCHEMBL5515215

SCHEMBL5515215

CCCC(=O)OCn1nc(C(=O)OCC)c(C(=O)c2cc(OC)c(OC)cc2N)n1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TNF P01375 7/20 0.41
KDM4E B2RXH2 2/20 0.40
DPP4 P27487 5/20 0.38
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
F2 P00734 1/20 0.36
PLAU P00749 1/20 0.36
ELANE P08246 1/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5512764 0.93 TNF (0.39) TNFKDM4EGAAALDH1A1HPGD
SCHEMBL5511478 0.93 TNF (0.39) TNFKDM4EGAAALDH1A1HPGD
SCHEMBL5512849 0.91 TNF (0.39) TNFKDM4EDPP4ALDH1A1HPGD
SCHEMBL6000183 0.90 KDM4E (0.39) TNFKDM4EDPP4ALDH1A1
SCHEMBL5512207 0.89 MYC (0.42) KDM4EDPP4GAAALDH1A1HPGD
SCHEMBL5516130 0.89 KDM4E (0.42) KDM4EDPP4GAAALDH1A1HPGD
SCHEMBL5524774 0.87 KDM4E (0.43) KDM4EDPP4GAAALDH1A1HPGD
SCHEMBL5511556 0.87 KDM4E (0.40) KDM4EDPP4GAAALDH1A1HPGD
SCHEMBL5512857 0.85 KDM4E (0.38) KDM4EDPP4GAAALDH1A1NPSR1
SCHEMBL5517826 0.85 MAPT (0.45) KDM4EGAAALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238812-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEJI SEIKA KAISHA, LTD. (JP) 2007-07-03 US disclosed
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2006-04-06 US disclosed
US-7022860-B2 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2002-09-26 US disclosed
US-6372735-B1 ANTIHISTAMINES MEIJI SEIKA KAISHA, LTD. (JP) 2002-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP2D6, CYP2B6 TNF 4043/4885KDM4E 752/4885DPP4 719/4885
US-20020137739-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP3A4, TPH1 TNF 4581/4885KDM4E 547/4885DPP4 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.